Orelabrutinib plus rituximab, cyclophosphamide, doxorubicin, and vincristine (R-CHOP) resulted in a high response rate with a tolerable safety profile in patients with extranodal, non-germinal center B-cell-like (GCB) diffuse large B-cell lymphoma (DLBCL), according to the results of a study presented at ESMO Congress 2022.
The trial included 22 patients with non-GCB DLBCL and confirmed extranodal disease. At baseline, the median age was 52 years, and 36.3% of patients were men. The majority of patients (86.4%) had stage IV disease, and 50% had an International Prognostic Index score of 3 to 5.
There were 54.5% of patients who had MYC/BCL2 double-expressing disease, and 13.6% had a TP53 mutation. The most common extranodal sites of invasion were the pericardium, pleura, or peritoneum (45.5%); gastrointestinal tract (27.3%); and kidney or adrenal gland (22.7%).
The patients received orelabrutinib plus R-CHOP on a 21-day cycle for 6 cycles. The primary endpoint was overall response rate (ORR), and the median follow-up was 11 months.
Orelabrutinib plus R-CHOP resulted in an ORR of 86.4%, and 77.3% of patients achieved a complete response (CR). Patients with double-expressor DLBCL had an ORR of 75%, and all responses were CRs.
The median progression-free survival (PFS) was not reached, and the 5-month PFS rate was 90.9%.
Serious adverse events included febrile neutropenia (13.6%), pneumonia (9.1%), and atrial flutter (4.5%).
Wang M, Ke Q, Li Z, et al. Orelabrutinib plus RCHOP for previously untreated non-germinal center B cell-like (GCB) diffuse large B-cell lymphoma (DLBCL) patients with extranodal disease. Presented at ESMO 2022; September 9-13, 2022. Abstract 627MO.
This article originally appeared on Hematology Advisor